World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
15191
World Ranking
3848
National Ranking
1764

Overview

Donald N. Forthal is affiliated with the University of California, Irvine in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with significant contributions to subfields such as Infectious Diseases, Immunology, Neurology, Virology, and Obstetrics and Gynecology.

The main topics covered in their work include COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19, HIV Research and Treatment, COVID-19 Impact on Reproduction, Immune Cell Function and Interaction, and COVID-19 and Mental Health.

Recent notable publications by Donald N. Forthal include:

  • Prevention and Treatment of Monkeypox (2022) published in Drugs
  • Pharmaco-Immunomodulatory Therapy in COVID-19 (2020) published in Drugs
  • Early Outpatient Treatment for Covid-19 with Convalescent Plasma (2022) published in New England Journal of Medicine
  • Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic (2020) published in Drug Discovery Today
  • Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study (2023) published in The Lancet Microbe

Frequent co-authors collaborating with Donald N. Forthal include:

  • David Sullivan
  • Kelly A. Gebo
  • Evan M. Bloch
  • Giselle Mosnaim
  • Yuriko Fukuta

Forthal's work has been published extensively in journals such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Drugs
  • mBio
  • Transfusion
  • Advanced Drug Delivery Reviews

Best Publications

  • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

    Neil M Flynn;Donald N Forthal;Clayton D Harro;Franklyn N Judson

  • Fc receptor but not complement binding is important in antibody protection against HIV

    Ann J. Hessell;Lars Hangartner;Meredith Hunter;Carin E. G. Havenith

  • Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

    Georgia D. Tomaras;Nicole L. Yates;Pinghuang Liu;Li Qin

  • The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.

    Haubrich Rh;Little Sj;Currier Js;Forthal Dn

  • Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

    Ann J. Hessell;Eva G. Rakasz;Pascal Poignard;Pascal Poignard;Lars Hangartner;Lars Hangartner

  • Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

    Jinyan Liu;Kara L. O’Brien;Diana M. Lynch;Nathaniel L. Simmons

  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

    Dan H. Barouch;Dan H. Barouch;Jinyan Liu;Hualin Li;Lori F. Maxfield

  • Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

    Ann J. Hessell;Eva G. Rakasz;David M. Tehrani;Michael Huber

  • Early Outpatient Treatment for Covid-19 with Convalescent Plasma

    Unknown

  • Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both

    Diane V. Havlir;Michael P. Dubé;Fred R. Sattler;Donald N. Forthal

  • Functions of Antibodies

    Donald N. Forthal

  • Pharmaco-Immunomodulatory Therapy in COVID-19.

    John G. Rizk;Kamyar Kalantar-Zadeh;Mandeep R. Mehra;Carl J. Lavie

  • Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells

    Donald N. Forthal;Gary Landucci;Eric S. Daar

  • Fluconazole Combined with Flucytosine for Treatment of Cryptococcal Meningitis in Patients with AIDS

    Larsen Ra;Bozzette Sa;Jones Be;Haghighat D

  • Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.

    Donald N. Forthal;Peter B. Gilbert;Gary Landucci;Tran Phan

  • Adjuvant-dependent Innate and Adaptive Immune Signatures of Risk of SIVmac251 Acquisition

    Monica Vaccari;Shari N Gordon;Slim Fourati;Luca Schifanella;Luca Schifanella

  • The Prevalence of Infection with Human Immunodeficiency Virus over a 10-Year Period in Rural Zaire

    N. Nzilambi;K. M. De Cock;D. N. Forthal;H. Francis

  • Fc receptor-mediated antiviral antibodies.

    Donald N Forthal;Christiane Moog

  • Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

    Cherie T Ng;J Pablo Jaworski;Pushpa Jayaraman;Pushpa Jayaraman;Pushpa Jayaraman;William F Sutton

  • Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

    Donald N. Forthal;Johannes S. Gach;Gary Landucci;Jakub Jez

  • A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

    Brian Moldt;Mami Shibata-Koyama;Eva G. Rakasz;Niccole Schultz

Frequent Co-Authors

David C. Montefiori
David C. Montefiori Duke University
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Guido Ferrari
Guido Ferrari Duke University
Dennis R. Burton
Dennis R. Burton Scripps Research Institute
David Venzon
David Venzon National Institutes of Health
Mario Roederer
Mario Roederer National Institute of Allergy and Infectious Diseases
Marjorie Robert-Guroff
Marjorie Robert-Guroff National Institutes of Health
Genoveffa Franchini
Genoveffa Franchini National Institutes of Health
Nancy L. Haigwood
Nancy L. Haigwood Oregon Health & Science University
Susan W. Barnett
Susan W. Barnett Bill & Melinda Gates Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related online degrees can open doors in healthcare and research. Nursing professionals, for example, can explore specialized programs such as accelerated NP programs to quickly advance their clinical skills and expertise.

Transitioning within nursing roles is also common. Nurses seeking to evolve from family practice to acute care settings might find guidance in pathways like fnp to acute care np transitions, which outline the necessary steps and education adjustments.

For newcomers to nursing, enrolling in online ADN programs for non nurses provides a flexible route to gain foundational knowledge and credentials, preparing them for further specialization including immunological studies.

Moreover, understanding financial prospects is crucial. Nurses and healthcare professionals considering Immunology-related careers should review state-wise earning potentials, such as dnp salary by state, to make informed decisions about their educational investments and career moves.

Best Scientists Citing Donald N. Forthal

Trending Scientists

Recently Published Articles